2023

Informational letter to healthcare professionals on the need to monitor metabolic processes, the increased risk of extrapyramidal symptoms and somnolence in patients taking medicinal products containing the active substance quetiapine

Information letter for healthcare professionals on the need to monitor metabolic processes, the risk of extrapyramidal symptoms and somnolence in patients using medicinal products containing quetiapine. generated automatically

Information letter for healthcare professionals on the safety of use of the medicinal product AMIODARONE

Information letter-appeal to healthcare professionals “Systemic and inhaled fluoroquinolones (ABIFLOX®)”

Information letter for healthcare professionals “Systemic antibacterial agents of the fluoroquinolone group (OFLOXACIN)

Updated additional risk minimization materials for the use of the medicinal product HUMIRA®

Informational notification letter on the increase in the number of reports of nausea and/or vomiting with the use of the medicinal product Integrilin (eptifibatide), informational notification letter on the discontinuation of production of the medicinal product Integrilin (eptifibatide)

Information notification letters about the increase in the number of cases of nausea and/or vomiting associated with the use of a medicinal product and about the discontinuation of its manufacture. Intended for healthcare professionals and patients. generated automatically

Risk of long-lasting serious adverse reactions: a reminder of restrictions on the use of antibacterial agents of the fluoroquinolone class (LEVOSTAD®))"

ACTIVE PHARMACOVIGILANCE for the medicinal product MIDOCALM, solution for injection

Antibacterial agents belonging to the fluoroquinolone group for systemic and inhalation use (ATOVAX®, OZERLIK®, POLIMIK®, TAIGERON®) – information on the risk of long-lasting serious adverse reactions and a reminder of restrictions on use

Information material on the risk of long-lasting serious adverse reactions with the use of systemic and inhaled fluoroquinolone antibacterial agents, and a reminder of restrictions on their use. Intended for healthcare professionals. generated automatically

Fluoroquinolones for systemic or inhaled use (OFLOXACIN EURO, LEVOFLOXACIN EURO) – reminder of restrictions on use (risk of long-lasting serious adverse reactions)